TAT

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies

Wednesday, October 20, 2021 - 9:05pm

HAMILTON, Ontario and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies (TATs) at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.

Key Points: 
  • These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.
  • Data from preclinical studies of FPI-1966, a TAT designed to target and deliver actinium-225 to cancer cells expressing FGFR3, were presented in an oral presentation titled, "FGFR3 Targeted Alpha Therapeutic [225Ac]-FPI-1966 induces regression in preclinical bladder xenograft model".
  • Further, the data showed therapeutic efficacy of FPI-1966 at both single and multiple doses in a preclinical bladder cancer xenograft model.
  • Data from preclinical studies of FPI-2059, a TAT designed to target and deliver actinium-225 to cancer cells expressing neurotensin receptor 1 (NTSR1), were presented in an oral presentation titled "NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 induces regression in preclinical colorectal xenograft model".

Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT

Tuesday, October 19, 2021 - 6:03am

Hitachi, Tohoku University, and Kyoto University will continue research and development efforts to bring this production technology into commercial use, to help put TAT into clinical practice and ultimately improve cancer patients' quality of life (QoL).

Key Points: 
  • Hitachi, Tohoku University, and Kyoto University will continue research and development efforts to bring this production technology into commercial use, to help put TAT into clinical practice and ultimately improve cancer patients' quality of life (QoL).
  • Hitachi makes effort to pursue research and development that promotes the Security & Safety (healthy and comfortable life for each individual) of society.
  • External radiation uses beams of radiation delivered outside the body to target cancer cells, while internal radiation involves internal delivery of radiation.
  • Research Center for Electron Photon Science (ELPH), Tohoku University Hidetoshi Kikunaga, Associate Professor
    Institute for Integrated Radiation and Nuclear Science, Kyoto University

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Monday, October 18, 2021 - 12:10pm

Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.

Key Points: 
  • Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.
  • ITM is a world leader in the development, production and global supply of radiotherapeutics and diagnostics, and maintains an evolving precision oncology pipeline.
  • Under the terms of the agreement, CNL will be responsible for the research and development as well as the production of Actinium-225.
  • CNL and ITM aim to leverage their capabilities towards establishing a continuous commercial supply of GMP-grade Actinium-225 for the global market.

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Monday, October 18, 2021 - 8:00am

Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.

Key Points: 
  • Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.
  • ITM is a world leader in the development, production and global supply of radiotherapeutics and diagnostics, and maintains an evolving precision oncology pipeline.
  • Under the terms of the agreement, CNL will be responsible for the research and development as well as the production of Actinium-225.
  • CNL and ITM aim to leverage their capabilities towards establishing a continuous commercial supply of GMP-grade Actinium-225 for the global market.

Master Vendor Platform, a Rising Solution for Tail Spend Optimization, Says Beroe

Thursday, October 14, 2021 - 2:00pm

With the surge of technology, the master vendor platform can effectively channel and optimize the tail spend purchases.

Key Points: 
  • With the surge of technology, the master vendor platform can effectively channel and optimize the tail spend purchases.
  • "Many businesses have begun to recognize the need for focussing technology to optimize tail spend management.
  • There are four ways of tail spend optimization: time-saving & increased compliance, management control, vendor consolidation, and cost savings & increased spend under management.
  • These are four definite ways technology-based master vendor platforms can optimize tail spend, giving organizations better control of their spending and providing them with more cost-saving opportunities.

Master Vendor Platform, a Rising Solution for Tail Spend Optimization, Says Beroe

Thursday, October 14, 2021 - 2:00pm

RALEIGH, N.C., Oct. 14, 2021 /PRNewswire/ -- Various industry verticals like Pharmaceutical, Automotive, CPG, Aerospace, Food & Beverage, Banking, and Financial Services are continuously exploring tech-backed vendor platforms to observe maximum tail spend optimization.  

Key Points: 
  • With the surge of technology, the master vendor platform can effectively channel and optimize the tail spend purchases.
  • "Many businesses have begun to recognize the need for focussing technology to optimize tail spend management.
  • There are four ways of tail spend optimization: time-saving & increased compliance, management control, vendor consolidation, and cost savings & increased spend under management.
  • These are four definite ways technology-based master vendor platforms can optimize tail spend, giving organizations better control of their spending and providing them with more cost-saving opportunities.

Precision Molecular Announces Publication of Preclinical Data Detailing Use of PMI06, a PD-L1 Imaging Agent, to Quantify Accessible Target Levels in Solid Tumors to Guide Therapy

Tuesday, September 28, 2021 - 12:00pm

The study also demonstrated how accessible target levels can be used to derive insights into pharmacologic activity of antibodies in tumors and elucidate therapeutic response.

Key Points: 
  • The study also demonstrated how accessible target levels can be used to derive insights into pharmacologic activity of antibodies in tumors and elucidate therapeutic response.
  • PMI06 is a radiolabeled peptide that binds to PD-L1, marking the ligand for visualization using positron emission tomography (PET) imaging.
  • There are several approved immune checkpoint inhibitors currently available to patients and more in development, said Seulki Lee, Ph.D., CEO of PMI.
  • Precision Molecular (PMI) is a clinical-stage company with the mission to develop imaging biomarkers and targeted alpha therapy (TAT) for cancer management.

Matternet and SkyGo partner with Abu Dhabi DoH for world's first city-wide medical drone network

Wednesday, September 22, 2021 - 2:10pm

ABU DHABI, UAE, Sept. 22, 2021 /PRNewswire/ --Today, Matternet announced a city-wide drone delivery network for the rapid transport of medical goods in Abu Dhabi, in collaboration with the Abu Dhabi Department of Health (DoH) and logistics company Skygo .

Key Points: 
  • ABU DHABI, UAE, Sept. 22, 2021 /PRNewswire/ --Today, Matternet announced a city-wide drone delivery network for the rapid transport of medical goods in Abu Dhabi, in collaboration with the Abu Dhabi Department of Health (DoH) and logistics company Skygo .
  • To bring its services to Abu Dhabi, Matternet, the global leader in urban drone delivery, has partnered with SkyGo, a UAE company with in-depth knowledge of the Abu Dhabi healthcare landscape and expertise in logistics and distribution in the Gulf region.
  • Notably, last month Matternet became the first drone company in the U.S. to start transporting the Pfizer-BioNTech COVID-19 vaccine by drone.
  • In November 2020, Matternet initiated the first permanent BVLOS medical drone network in the European Union with Labor Berlin.

Samsung Foundry Certifies Synopsys PrimeLib Unified Library Characterization and Validation Solution at 5nm, 4nm and 3nm Process Nodes

Wednesday, September 22, 2021 - 2:05pm

With compute demands growing 3x as each node advances, library characterization complexity has dramatically increased.

Key Points: 
  • With compute demands growing 3x as each node advances, library characterization complexity has dramatically increased.
  • The next-generation solution also includes innovative SmartScaling technology for multi-PVT characterization, built on top of the Synopsys PrimeTime scaling engine to enable instant library generation with minimum characterized corners.
  • "The Synopsys PrimeLib library characterization and validation solution enables us to deliver signoff-quality libraries for these advanced nodes up to 5x faster.
  • For more information, visit PrimeLib: Unified Library Characterization and Validation .

BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225

Thursday, September 16, 2021 - 11:45am

BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.

Key Points: 
  • BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
  • BWXT Medical plans to utilize its deep relationships with strategic partners in irradiation services and development of Ac-225.
  • Much like BWXT Medicals other products, processing and manufacturing would then be conducted at BWXT Medical facilities.